FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281290250> ?p ?o ?g. }

• W4281290250 abstract "Abstract Importance National Institute on Aging-Alzheimer’s Association (NIA-AA) workgroups have proposed biological research criteria intended to identify individuals with preclinical Alzheimer’s disease (AD). Objective Assess the clinical value of these biological criteria for prediction of near-term cognitive impairment in cognitively unimpaired older individuals. Design, Setting, and Participants We studied 580 cognitively unimpaired older adults from four independent cohorts (PREVENT-AD: 128; HABS: 153; AIBL: 48; Knight ADRC: 251) having ≥1 year of clinical observation following Aβ and tau PET (median follow-up: PREVENT-AD = 3.16 yrs [1.51-4.50]; HABS = 1.94yrs [1.13-5.42]; AIBL = 3.66yrs [1.72-5.98]); Knight ADRC = 3.01 yrs [1.04-6.20]). Exposures Based on binary assessment of global amyloid burden (A) and of a composite temporal region of tau PET uptake (T), we stratified participants into four groups (A+T+, A+T-, A-T+, A-T-). Presence (+) or absence (-) of neurodegeneration (N) was assessed using temporal cortical thickness. Main Outcomes and Measures We analyzed each cohort separately. Primary outcome was clinical progression to mild cognitive impairment (MCI). A secondary outcome was cognitive decline. We compared MCI progression and cognitive decline across the four biomarker groups. MCI was identified by consensus committee review in PREVENT-AD, HABS, and AIBL, and by a CDR ≥ 0.5 in Knight ADRC. Clinical raters were blinded to imaging, genetic, and fluid biomarker data. Using a composite measure, cognitive decline was identified by a slope >1 SD below that of A-T- ‘non-progressors’. Results Across cohorts, 32 - 83% of A+T+ participants progressed to MCI during follow-up (mean progression time 2.0 - 2.72 years), as compared with <12% of participants in other biomarker groups. In two cohorts, progression increased to 100% when A+T+ individuals were also (N+). Cox proportional hazard ratios for progression to MCI in the A+T+ group vs. other biomarker groups were >5. Many A+T+ ‘non-progressors’ nonetheless showed longitudinal cognitive decline, while cognitive trajectories in other groups remained predominantly stable. Conclusions and Relevance Clinical prognostic value of the NIA-AA research criteria was confirmed in four independent cohorts, with nearly all A+T+(N+) cognitively unimpaired older individuals developing AD symptoms within ∼2-3 years. Key Points Question What is the clinical relevance of the AT(N) biological classification of Alzheimer’s disease (AD) in unimpaired older adults? Findings In this prospective study of 580 cognitively unimpaired participants from four independent cohorts, between 31.58 and 100% of A+T+(N+) participants progressed to mild cognitive impairment (MCI) within 2-3 years after PET. The majority of A+T+ non-progressors also showed cognitive decline. Meaning Cognitively unimpaired older adults with biological AD are at imminent risk of developing MCI. These individuals may be ideal candidates for disease modifying therapies." @default.
• W4281290250 created "2022-05-24" @default.
• W4281290250 creator A5000597778 @default.
• W4281290250 creator A5000636220 @default.
• W4281290250 creator A5001795846 @default.
• W4281290250 creator A5014524757 @default.
• W4281290250 creator A5022818431 @default.
• W4281290250 creator A5031128323 @default.
• W4281290250 creator A5033253171 @default.
• W4281290250 creator A5035544819 @default.
• W4281290250 creator A5036473548 @default.
• W4281290250 creator A5045301373 @default.
• W4281290250 creator A5057796570 @default.
• W4281290250 creator A5058052951 @default.
• W4281290250 creator A5063630764 @default.
• W4281290250 creator A5069288852 @default.
• W4281290250 creator A5071806329 @default.
• W4281290250 creator A5082544855 @default.
• W4281290250 creator A5084902960 @default.
• W4281290250 creator A5087983425 @default.
• W4281290250 creator A5090741969 @default.
• W4281290250 creator A5090842068 @default.
• W4281290250 date "2022-05-11" @default.
• W4281290250 modified "2023-10-09" @default.
• W4281290250 title "AT(N) predicts near-term development of Alzheimer’s disease symptoms in unimpaired older adults" @default.
• W4281290250 cites W1517352381 @default.
• W4281290250 cites W1847168837 @default.
• W4281290250 cites W1971032265 @default.
• W4281290250 cites W2031407059 @default.
• W4281290250 cites W2051737015 @default.
• W4281290250 cites W2052742260 @default.
• W4281290250 cites W2101135654 @default.
• W4281290250 cites W2102719061 @default.
• W4281290250 cites W2152223730 @default.
• W4281290250 cites W2215958284 @default.
• W4281290250 cites W2412942072 @default.
• W4281290250 cites W2510806376 @default.
• W4281290250 cites W2529649944 @default.
• W4281290250 cites W2765181675 @default.
• W4281290250 cites W2798054687 @default.
• W4281290250 cites W2892120842 @default.
• W4281290250 cites W2912582321 @default.
• W4281290250 cites W2961942506 @default.
• W4281290250 cites W2997283194 @default.
• W4281290250 cites W3004011133 @default.
• W4281290250 cites W3113674672 @default.
• W4281290250 cites W3159530258 @default.
• W4281290250 cites W3167322081 @default.
• W4281290250 cites W3203244102 @default.
• W4281290250 doi "https://doi.org/10.1101/2022.05.09.22274638" @default.
• W4281290250 hasPublicationYear "2022" @default.
• W4281290250 type Work @default.
• W4281290250 citedByCount "2" @default.
• W4281290250 countsByYear W42812902502022 @default.
• W4281290250 crossrefType "posted-content" @default.
• W4281290250 hasAuthorship W4281290250A5000597778 @default.
• W4281290250 hasAuthorship W4281290250A5000636220 @default.
• W4281290250 hasAuthorship W4281290250A5001795846 @default.
• W4281290250 hasAuthorship W4281290250A5014524757 @default.
• W4281290250 hasAuthorship W4281290250A5022818431 @default.
• W4281290250 hasAuthorship W4281290250A5031128323 @default.
• W4281290250 hasAuthorship W4281290250A5033253171 @default.
• W4281290250 hasAuthorship W4281290250A5035544819 @default.
• W4281290250 hasAuthorship W4281290250A5036473548 @default.
• W4281290250 hasAuthorship W4281290250A5045301373 @default.
• W4281290250 hasAuthorship W4281290250A5057796570 @default.
• W4281290250 hasAuthorship W4281290250A5058052951 @default.
• W4281290250 hasAuthorship W4281290250A5063630764 @default.
• W4281290250 hasAuthorship W4281290250A5069288852 @default.
• W4281290250 hasAuthorship W4281290250A5071806329 @default.
• W4281290250 hasAuthorship W4281290250A5082544855 @default.
• W4281290250 hasAuthorship W4281290250A5084902960 @default.
• W4281290250 hasAuthorship W4281290250A5087983425 @default.
• W4281290250 hasAuthorship W4281290250A5090741969 @default.
• W4281290250 hasAuthorship W4281290250A5090842068 @default.
• W4281290250 hasBestOaLocation W42812902501 @default.
• W4281290250 hasConcept C118552586 @default.
• W4281290250 hasConcept C126322002 @default.
• W4281290250 hasConcept C143998085 @default.
• W4281290250 hasConcept C15744967 @default.
• W4281290250 hasConcept C169900460 @default.
• W4281290250 hasConcept C2776925932 @default.
• W4281290250 hasConcept C2779134260 @default.
• W4281290250 hasConcept C2779483572 @default.
• W4281290250 hasConcept C2781197716 @default.
• W4281290250 hasConcept C2984863031 @default.
• W4281290250 hasConcept C502032728 @default.
• W4281290250 hasConcept C55493867 @default.
• W4281290250 hasConcept C71924100 @default.
• W4281290250 hasConcept C72563966 @default.
• W4281290250 hasConcept C74909509 @default.
• W4281290250 hasConcept C86803240 @default.
• W4281290250 hasConceptScore W4281290250C118552586 @default.
• W4281290250 hasConceptScore W4281290250C126322002 @default.
• W4281290250 hasConceptScore W4281290250C143998085 @default.
• W4281290250 hasConceptScore W4281290250C15744967 @default.
• W4281290250 hasConceptScore W4281290250C169900460 @default.
• W4281290250 hasConceptScore W4281290250C2776925932 @default.
• W4281290250 hasConceptScore W4281290250C2779134260 @default.
• W4281290250 hasConceptScore W4281290250C2779483572 @default.

• next